Medical treatment of Parkinson's disease: today and the future.
Idiopathic Parkinson's disease (PD) is the only neurodegenerative disorder for which highly effective symptomatic therapy is available. Although levodopa continues to be the gold standard of symptomatic efficacy for treatment of the cardinal motor features, its chronic use is associated with potentially disabling motor complications. This review provides a survey of the medication that can currently be utilized for pharmacological management of the motor and non-motor symptoms of Parkinson's disease. Focus is placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of such medication, and on how such studies may impact the future management of Parkinson's disease.
Gárdián
G
G
Department of Neurology, University of Szeged, Szeged, Hungary.
Vécsei
L
L
D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007737:Kynurenine / Q000502:physiology; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007737:Kynurenine; D007980:Levodopa